Bellicum Pharmaceuticals Stock Probability Of Bankruptcy
| BLCMDelisted Stock | USD 0.37 0.05 11.90% |
Bellicum |
Bellicum Pharmaceuticals Company odds of distress Analysis
Bellicum Pharmaceuticals' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Bellicum Pharmaceuticals Probability Of Bankruptcy | Over 100% |
Most of Bellicum Pharmaceuticals' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bellicum Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Bellicum Pharmaceuticals probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Bellicum Pharmaceuticals odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Bellicum Pharmaceuticals financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
CompetitionBased on the latest financial disclosure, Bellicum Pharmaceuticals has a Probability Of Bankruptcy of 100%. This is 131.0% higher than that of the Biotechnology sector and 82.35% higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 151.07% lower than that of the firm.
Bellicum Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bellicum Pharmaceuticals' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bellicum Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Bellicum Pharmaceuticals by comparing valuation metrics of similar companies.Bellicum Pharmaceuticals is currently under evaluation in probability of bankruptcy category among its peers.
Bellicum Fundamentals
| Return On Equity | -1.06 | |||
| Return On Asset | -0.61 | |||
| Operating Margin | (19.69) % | |||
| Current Valuation | (38.62 M) | |||
| Shares Outstanding | 9.5 M | |||
| Shares Owned By Insiders | 4.19 % | |||
| Shares Owned By Institutions | 29.30 % | |||
| Number Of Shares Shorted | 1.44 M | |||
| Price To Earning | 8.50 X | |||
| Price To Book | 1.00 X | |||
| Price To Sales | 5.46 X | |||
| Revenue | 1.5 M | |||
| Gross Profit | (17.38 M) | |||
| EBITDA | (28.93 M) | |||
| Net Income | (24.97 M) | |||
| Cash And Equivalents | 33.17 M | |||
| Cash Per Share | 3.85 X | |||
| Total Debt | 58 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 8.07 X | |||
| Book Value Per Share | (1.11) X | |||
| Cash Flow From Operations | (25.78 M) | |||
| Short Ratio | 0.17 X | |||
| Earnings Per Share | (1.57) X | |||
| Target Price | 5.0 | |||
| Number Of Employees | 13 | |||
| Beta | 1.57 | |||
| Market Capitalization | 3.52 M | |||
| Total Asset | 23.82 M | |||
| Retained Earnings | (575.42 M) | |||
| Working Capital | 20.03 M | |||
| Current Asset | 96.89 M | |||
| Current Liabilities | 7.45 M | |||
| Z Score | -0.31 | |||
| Net Asset | 23.82 M |
About Bellicum Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bellicum Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bellicum Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bellicum Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Bellicum Pink Sheet
If you are still planning to invest in Bellicum Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellicum Pharmaceuticals' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |